A Clinical Perspective on Arsenic Exposure and Development of Atherosclerotic Cardiovascular Disease.

Autor: Kaur G; Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA., Desai KP; Division of Cardiovascular Medicine, University of Maryland, Baltimore, MD, USA., Chang IY; Stuyvesant High School, New York, NY, USA., Newman JD; Division of Cardiology, New York University School of Medicine, New York, NY, USA., Mathew RO; Division of Nephrology, Loma Linda VA Health Care System, Loma Linda, CA, USA., Bangalore S; Division of Cardiology, New York University School of Medicine, New York, NY, USA., Venditti FJ; Division of Cardiology, Department of Medicine, Albany Medical College and Albany Medical Center, Albany, NY, USA., Sidhu MS; Division of Cardiology, Department of Medicine, Albany Medical College and Albany Medical Center, Albany, NY, USA. sidhum@amc.edu.
Jazyk: angličtina
Zdroj: Cardiovascular drugs and therapy [Cardiovasc Drugs Ther] 2023 Dec; Vol. 37 (6), pp. 1167-1174. Date of Electronic Publication: 2022 Jan 14.
DOI: 10.1007/s10557-021-07313-9
Abstrakt: Cardiovascular risk has traditionally been defined by modifiable and non-modifiable risk factors, such as tobacco use, hyperlipidemia, and family history. However, chemicals and pollutants may also play a role in cardiovascular disease (CVD) risk. Arsenic is a naturally occurring element that is widely distributed in the Earth's crust. Inorganic arsenic (iAs) has been implicated in the pathogenesis of atherosclerosis, with chronic high-dose exposure to iAs (> 100 µg/L) being linked to CVD; however, whether low-to-moderate dose exposures of iAs (< 100 µg/L) are associated with the development of CVD is unclear. Due to limitations of the existing literature, it is difficult to define a threshold for iAs toxicity. Studies demonstrate that the effect of iAs on CVD is far more complex with influences from several factors, including diet, genetics, metabolism, and traditional risk factors such as hypertension and smoking. In this article, we review the existing data of low-to-moderate dose iAs exposure and its effect on CVD, along with highlighting the potential mechanisms of action.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: